Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05490472 · ClinicalTrials.gov registry record · Phase 1

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

A Phase 1 study of Solid Tumors and Triple Negative Breast Cancer (TNBC), sponsored by Jacobio Pharmaceuticals Co..

Recruiting
Registry status
Phase 1
Development phase
102
Enrollment target
8
Study locations

NCT05490472 is a Phase 1 study of Solid Tumors and Triple Negative Breast Cancer (TNBC) that is actively recruiting participants, run by Jacobio Pharmaceuticals Co.. The registered enrollment target is 102 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (64% lower). The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05490472, a Phase 1 study of Solid Tumors and Triple Negative Breast Cancer (TNBC), is actively recruiting participants, sponsored by Jacobio Pharmaceuticals Co..

RECRUITING
Registry status
Phase 1
Development phase
102 participants
Enrollment target
8
Study locations

Study Summary

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

Conditions Studied

Solid Tumors Triple Negative Breast Cancer (TNBC) Small Cell Lung Cancer (SCLC) ER+ Breast Cancer ARID1A Gene Mutation

Interventions

  • DRUG JAB-2485 (Aurora A inhibitor)

Study Locations (8)

Beijing Municipality

  • Cancer Hospital Chinese Academy of Medical Sciences - Beijing
  • Peking University Third Hospital - Beijing

Michigan

  • Henry Ford Health System - Detroit

Missouri

  • Washington University - St Louis

Texas

  • Mary Crowley Cancer Research - Dallas

Utah

  • University of Utah Huntsman Cancer Institute - Salt Lake City

Jilin

  • Jilin Cancer Hospital - Changchun

Shandong

  • Shandong Cancer Hospital - Jinan

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2022-12-20
Est. Completion 2027-08
Phase Phase 1

Sponsor

Jacobio Pharmaceuticals Co.

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05490472

The ClinicalTrials.gov registry entry for NCT05490472 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (64% lower). The listed sponsor is Jacobio Pharmaceuticals Co., which has 7 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which JAB-2485 (Aurora A inhibitor) is the first listed.

NCT05490472 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Beijing Municipality, Michigan, Missouri.

Frequently Asked Questions

What is clinical trial NCT05490472 about?

NCT05490472 is a clinical study titled "JAB-2485 Activity in Adult Patients With Advanced Solid Tumors". This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

What is the current status of trial NCT05490472?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2022-12-20. Estimated completion is 2027-08.

What conditions does trial NCT05490472 study?

This clinical trial studies the following conditions: Solid Tumors, Triple Negative Breast Cancer (TNBC), Small Cell Lung Cancer (SCLC), ER+ Breast Cancer, ARID1A Gene Mutation.

What interventions are being tested in trial NCT05490472?

The interventions under investigation include: JAB-2485 (Aurora A inhibitor) (DRUG).

Who is sponsoring clinical trial NCT05490472?

This trial is sponsored by Jacobio Pharmaceuticals Co., which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05490472 being conducted?

This trial has 8 study locations across Michigan, Missouri, Texas, Utah, Beijing Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Triple Negative Breast Cancer (TNBC)

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.